Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Semisynthetic Antimycobacterial C-3 Silicate and C-3/C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma, and Mycobacterium tuberculosis culture.

Njoroge M, Kaur G, Espinoza-Moraga M, Wasuna A, Dziwornu GA, Seldon R, Taylor D, Okombo J, Warner DF, Chibale K.

ACS Infect Dis. 2019 Jul 29. doi: 10.1021/acsinfecdis.9b00208. [Epub ahead of print]

PMID:
31309823
3.

Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: Antimicrobial evaluation and mechanistic insights.

Baartzes N, Stringer T, Seldon R, Warner DF, Taylor D, Wittlin S, Chibale K, Smith GS.

Eur J Med Chem. 2019 Jun 26;180:121-133. doi: 10.1016/j.ejmech.2019.06.069. [Epub ahead of print]

PMID:
31301563
4.

Azaaurones as Potent Antimycobacterial Agents Active against MDR- and XDR-TB.

Campaniço A, Carrasco MP, Njoroge M, Seldon R, Chibale K, Perdigão J, Portugal I, Warner DF, Moreira R, Lopes F.

ChemMedChem. 2019 Jul 11. doi: 10.1002/cmdc.201900289. [Epub ahead of print]

PMID:
31294529
5.

Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles.

Attram HD, Wittlin S, Chibale K.

Medchemcomm. 2019 Feb 19;10(3):450-455. doi: 10.1039/c8md00608c. eCollection 2019 Mar 1.

PMID:
31015908
6.

Cocrystal and Salt Forms of an Imidazopyridazine Antimalarial Drug Lead.

Noonan TJ, Chibale K, Cheuka PM, Bourne SA, Caira MR.

J Pharm Sci. 2019 Jul;108(7):2349-2357. doi: 10.1016/j.xphs.2019.02.006. Epub 2019 Feb 25.

PMID:
30817923
7.

Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl.

Paccez JD, Duncan K, Sekar D, Correa RG, Wang Y, Gu X, Bashin M, Chibale K, Libermann TA, Zerbini LF.

Oncogenesis. 2019 Feb 19;8(3):14. doi: 10.1038/s41389-019-0122-6.

8.

Antimalarial Pyrido[1,2- a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies.

Okombo J, Brunschwig C, Singh K, Dziwornu GA, Barnard L, Njoroge M, Wittlin S, Chibale K.

ACS Infect Dis. 2019 Mar 8;5(3):372-384. doi: 10.1021/acsinfecdis.8b00279. Epub 2019 Jan 17.

PMID:
30608648
9.
10.

Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of Malaria.

Mayoka G, Njoroge M, Okombo J, Gibhard L, Sanches-Vaz M, Fontinha D, Birkholtz LM, Reader J, van der Watt M, Coetzer TL, Lauterbach S, Churchyard A, Bezuidenhout B, Egan TJ, Yeates C, Wittlin S, Prudêncio M, Chibale K.

J Med Chem. 2019 Jan 24;62(2):1022-1035. doi: 10.1021/acs.jmedchem.8b01769. Epub 2018 Dec 24.

PMID:
30562027
11.

Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of Action.

Kumar M, Okombo J, Mambwe D, Taylor D, Lawrence N, Reader J, van der Watt M, Fontinha D, Sanches-Vaz M, Bezuidenhout BC, Lauterbach SB, Liebenberg D, Birkholtz LM, Coetzer TL, Prudêncio M, Egan TJ, Wittlin S, Chibale K.

ACS Infect Dis. 2019 Feb 8;5(2):303-315. doi: 10.1021/acsinfecdis.8b00272. Epub 2019 Jan 7.

PMID:
30525439
12.

Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.

Cheuka PM, Lawrence N, Taylor D, Wittlin S, Chibale K.

Medchemcomm. 2018 Sep 6;9(10):1733-1745. doi: 10.1039/c8md00382c. eCollection 2018 Oct 1.

PMID:
30429978
13.

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01941-18. doi: 10.1128/AAC.01941-18. Print 2018 Nov. No abstract available.

14.

Structure-activity relationship studies of antiplasmodial cyclometallated ruthenium(II), rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles.

Rylands LI, Welsh A, Maepa K, Stringer T, Taylor D, Chibale K, Smith GS.

Eur J Med Chem. 2019 Jan 1;161:11-21. doi: 10.1016/j.ejmech.2018.10.019. Epub 2018 Oct 10.

PMID:
30342422
15.

The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries.

Pillai G, Chibale K, Constable EC, Keller AN, Gutierrez MM, Mirza F, Sengstag C, Masimirembwa C, Denti P, Maartens G, Ramsay M, Ogutu B, Makonnen E, Gordon R, Ferreira CG, Goldbaum FA, Degrave WMS, Spector J, Tadmor B, Kaiser HJ.

BMC Med Educ. 2018 Oct 10;18(1):233. doi: 10.1186/s12909-018-1331-y.

16.

Correction: Recent updates in the discovery and development of novel antimalarial drug candidates.

Okombo J, Chibale K.

Medchemcomm. 2018 Mar 2;9(3):590. doi: 10.1039/c8md90009d. eCollection 2018 Mar 1.

17.

Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.

Le Manach C, Paquet T, Wicht K, Nchinda AT, Brunschwig C, Njoroge M, Gibhard L, Taylor D, Lawrence N, Wittlin S, Eyermann CJ, Basarab GS, Duffy J, Fish PV, Street LJ, Chibale K.

J Med Chem. 2018 Oct 25;61(20):9371-9385. doi: 10.1021/acs.jmedchem.8b01333. Epub 2018 Oct 16.

PMID:
30256636
18.

Investigating Sulfoxide-to-Sulfone Conversion as a Prodrug Strategy for a Phosphatidylinositol 4-Kinase Inhibitor in a Humanized Mouse Model of Malaria.

Gibhard L, Njoroge M, Paquet T, Brunschwig C, Taylor D, Lawrence N, Abay E, Wittlin S, Wiesner L, Street LJ, Chibale K, Basarab GS.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00261-18. doi: 10.1128/AAC.00261-18. Print 2018 Dec.

19.

Recent updates in the discovery and development of novel antimalarial drug candidates.

Okombo J, Chibale K.

Medchemcomm. 2018 Feb 2;9(3):437-453. doi: 10.1039/c7md00637c. eCollection 2018 Mar 1. Review. Erratum in: Medchemcomm. 2018 Mar 2;9(3):590.

20.

3D-QSAR Modeling and Synthesis of New Fusidic Acid Derivatives as Antiplasmodial Agents.

Kaur G, Pavadai E, Wittlin S, Chibale K.

J Chem Inf Model. 2018 Aug 27;58(8):1553-1560. doi: 10.1021/acs.jcim.8b00105. Epub 2018 Aug 7.

PMID:
30040885
21.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00012-18. doi: 10.1128/AAC.00012-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11):.

22.

Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.

Kandepedu N, Gonzàlez Cabrera D, Eedubilli S, Taylor D, Brunschwig C, Gibhard L, Njoroge M, Lawrence N, Paquet T, Eyermann CJ, Spangenberg T, Basarab GS, Street LJ, Chibale K.

J Med Chem. 2018 Jul 12;61(13):5692-5703. doi: 10.1021/acs.jmedchem.8b00648. Epub 2018 Jun 27.

PMID:
29889526
23.

Plasmodial Kinase Inhibitors: License to Cure?

Cabrera DG, Horatscheck A, Wilson CR, Basarab G, Eyermann CJ, Chibale K.

J Med Chem. 2018 Sep 27;61(18):8061-8077. doi: 10.1021/acs.jmedchem.8b00329. Epub 2018 Jun 4.

24.

Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis.

Martinez-Grau MA, Valcarcel ICG, Early JV, Gessner RK, de Melo CS, de la Nava EMM, Korkegian A, Ovechkina Y, Flint L, Gravelle A, Cramer JW, Desai PV, Street LJ, Odingo J, Masquelin T, Chibale K, Parish T.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1758-1764. doi: 10.1016/j.bmcl.2018.04.028. Epub 2018 Apr 13.

25.

Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.

Nchinda AT, Le Manach C, Paquet T, Gonzàlez Cabrera D, Wicht KJ, Brunschwig C, Njoroge M, Abay E, Taylor D, Lawrence N, Wittlin S, Jiménez-Díaz MB, Santos Martínez M, Ferrer S, Angulo-Barturen I, Lafuente-Monasterio MJ, Duffy J, Burrows J, Street LJ, Chibale K.

J Med Chem. 2018 May 10;61(9):4213-4227. doi: 10.1021/acs.jmedchem.8b00382. Epub 2018 Apr 27.

PMID:
29665687
26.

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization.

Murugesan D, Ray PC, Bayliss T, Prosser GA, Harrison JR, Green K, Soares de Melo C, Feng TS, Street LJ, Chibale K, Warner DF, Mizrahi V, Epemolu O, Scullion P, Ellis L, Riley J, Shishikura Y, Ferguson L, Osuna-Cabello M, Read KD, Green SR, Lamprecht DA, Finin PM, Steyn AJC, Ioerger TR, Sacchettini J, Rhee KY, Arora K, Barry CE 3rd, Wyatt PG, Boshoff HIM.

ACS Infect Dis. 2018 Jun 8;4(6):954-969. doi: 10.1021/acsinfecdis.7b00275. Epub 2018 Mar 26.

27.

Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity.

Cozier GE, Schwager SL, Sharma RK, Chibale K, Sturrock ED, Acharya KR.

FEBS J. 2018 Apr;285(8):1477-1490. doi: 10.1111/febs.14421. Epub 2018 Mar 8.

28.

Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity.

Chopra R, Chibale K, Singh K.

Eur J Med Chem. 2018 Mar 25;148:39-53. doi: 10.1016/j.ejmech.2018.02.021. Epub 2018 Feb 9.

PMID:
29454189
29.

Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials.

van der Watt ME, Reader J, Churchyard A, Nondaba SH, Lauterbach SB, Niemand J, Abayomi S, van Biljon RA, Connacher JI, van Wyk RDJ, Le Manach C, Paquet T, González Cabrera D, Brunschwig C, Theron A, Lozano-Arias S, Rodrigues JFI, Herreros E, Leroy D, Duffy J, Street LJ, Chibale K, Mancama D, Coetzer TL, Birkholtz LM.

J Antimicrob Chemother. 2018 May 1;73(5):1279-1290. doi: 10.1093/jac/dky008.

PMID:
29420756
30.

Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis.

Kumar M, Singh K, Ngwane AH, Hamzabegovic F, Abate G, Baker B, Wiid I, Hoft DF, Ruminski P, Chibale K.

Bioorg Med Chem. 2018 Feb 15;26(4):833-844. doi: 10.1016/j.bmc.2017.12.047. Epub 2017 Dec 29.

PMID:
29373270
31.

The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme.

Fienberg S, Cozier GE, Acharya KR, Chibale K, Sturrock ED.

J Med Chem. 2018 Jan 11;61(1):344-359. doi: 10.1021/acs.jmedchem.7b01478. Epub 2017 Dec 21.

PMID:
29206036
32.

4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.

Joshi MC, Okombo J, Nsumiwa S, Ndove J, Taylor D, Wiesner L, Hunter R, Chibale K, Egan TJ.

J Med Chem. 2017 Dec 28;60(24):10245-10256. doi: 10.1021/acs.jmedchem.7b01537. Epub 2017 Dec 7.

PMID:
29185748
33.

Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.

Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE 3rd, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K.

J Med Chem. 2017 Dec 28;60(24):10118-10134. doi: 10.1021/acs.jmedchem.7b01347. Epub 2017 Dec 7.

34.

Antimicrobial activity of organometallic isonicotinyl and pyrazinyl ferrocenyl-derived complexes.

Stringer T, Seldon R, Liu N, Warner DF, Tam C, Cheng LW, Land KM, Smith PJ, Chibale K, Smith GS.

Dalton Trans. 2017 Aug 14;46(30):9875-9885. doi: 10.1039/c7dt01952a. Epub 2017 Jul 17.

PMID:
28713884
35.

Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery.

Okombo J, Chibale K.

Acc Chem Res. 2017 Jul 18;50(7):1606-1616. doi: 10.1021/acs.accounts.6b00631. Epub 2017 Jun 21.

36.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes.

Muñoz-Torrero D, Mangoni AA, Guillou C, Collina S, Vanden Eynde JJ, Rautio J, Keserű GM, Hulme C, Chibale K, Luque FJ, Karaman R, Gütschow M, Liu H, Ragno R.

Molecules. 2017 May 5;22(5). pii: E743. doi: 10.3390/molecules22050743.

37.

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.

Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ, Bantscheff M, Ruecker A, Blagborough AM, Zakutansky SE, Zeeman AM, White KL, Shackleford DM, Mannila J, Morizzi J, Scheurer C, Angulo-Barturen I, Martínez MS, Ferrer S, Sanz LM, Gamo FJ, Reader J, Botha M, Dechering KJ, Sauerwein RW, Tungtaeng A, Vanachayangkul P, Lim CS, Burrows J, Witty MJ, Marsh KC, Bodenreider C, Rochford R, Solapure SM, Jiménez-Díaz MB, Wittlin S, Charman SA, Donini C, Campo B, Birkholtz LM, Hanson KK, Drewes G, Kocken CHM, Delves MJ, Leroy D, Fidock DA, Waterson D, Street LJ, Chibale K.

Sci Transl Med. 2017 Apr 26;9(387). pii: eaad9735. doi: 10.1126/scitranslmed.aad9735.

38.

Antischistosomal Activity of Pyrido[1,2-a]benzimidazole Derivatives and Correlation with Inhibition of β-Hematin Formation.

Okombo J, Singh K, Mayoka G, Ndubi F, Barnard L, Njogu PM, Njoroge M, Gibhard L, Brunschwig C, Vargas M, Keiser J, Egan TJ, Chibale K.

ACS Infect Dis. 2017 Jun 9;3(6):411-420. doi: 10.1021/acsinfecdis.6b00205. Epub 2017 May 3.

PMID:
28440625
39.

Intestinal Transport Characteristics and Metabolism of C-Glucosyl Dihydrochalcone, Aspalathin.

Bowles S, Joubert E, de Beer D, Louw J, Brunschwig C, Njoroge M, Lawrence N, Wiesner L, Chibale K, Muller C.

Molecules. 2017 Mar 30;22(4). pii: E554. doi: 10.3390/molecules22040554.

40.

Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.

Pavadai E, Kaur G, Wittlin S, Chibale K.

Medchemcomm. 2017 Mar 22;8(6):1152-1157. doi: 10.1039/c7md00063d. eCollection 2017 Jun 1.

41.

Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents.

Vreese R, Kock C, Smith PJ, Chibale K, D'hooghe M.

Future Med Chem. 2017 Mar;9(4):357-364. doi: 10.4155/fmc-2016-0215. Epub 2017 Mar 6.

PMID:
28263085
42.

Synthesis and biological evaluation of 4 arylcoumarin analogues as tubulin-targeting antitumor agents.

Mutai P, Breuzard G, Pagano A, Allegro D, Peyrot V, Chibale K.

Bioorg Med Chem. 2017 Mar 1;25(5):1652-1665. doi: 10.1016/j.bmc.2017.01.035. Epub 2017 Jan 27.

PMID:
28174064
43.

Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.

Singh K, Okombo J, Brunschwig C, Ndubi F, Barnard L, Wilkinson C, Njogu PM, Njoroge M, Laing L, Machado M, Prudêncio M, Reader J, Botha M, Nondaba S, Birkholtz LM, Lauterbach S, Churchyard A, Coetzer TL, Burrows JN, Yeates C, Denti P, Wiesner L, Egan TJ, Wittlin S, Chibale K.

J Med Chem. 2017 Feb 23;60(4):1432-1448. doi: 10.1021/acs.jmedchem.6b01641. Epub 2017 Feb 7.

PMID:
28094524
44.

The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.

Cheuka PM, Mayoka G, Mutai P, Chibale K.

Molecules. 2016 Dec 31;22(1). pii: E58. doi: 10.3390/molecules22010058. Review.

45.

Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.

Espinoza-Moraga M, Singh K, Njoroge M, Kaur G, Okombo J, De Kock C, Smith PJ, Wittlin S, Chibale K.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):658-661. doi: 10.1016/j.bmcl.2016.11.077. Epub 2016 Nov 25.

PMID:
28012840
46.

The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.

Sharma RK, Espinoza-Moraga M, Poblete H, Douglas RG, Sturrock ED, Caballero J, Chibale K.

J Chem Inf Model. 2016 Dec 27;56(12):2486-2494. doi: 10.1021/acs.jcim.6b00524. Epub 2016 Dec 13.

PMID:
27959521
47.

Bioisosteric ferrocenyl-containing quinolines with antiplasmodial and antitrichomonal properties.

Adams M, Stringer T, de Kock C, Smith PJ, Land KM, Liu N, Tam C, Cheng LW, Njoroge M, Chibale K, Smith GS.

Dalton Trans. 2016 Nov 29;45(47):19086-19095.

PMID:
27858010
48.

Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.

Le Manach C, Nchinda AT, Paquet T, Gonzàlez Cabrera D, Younis Y, Han Z, Bashyam S, Zabiulla M, Taylor D, Lawrence N, White KL, Charman SA, Waterson D, Witty MJ, Wittlin S, Botha ME, Nondaba SH, Reader J, Birkholtz LM, Jiménez-Díaz MB, Martínez MS, Ferrer S, Angulo-Barturen I, Meister S, Antonova-Koch Y, Winzeler EA, Street LJ, Chibale K.

J Med Chem. 2016 Nov 10;59(21):9890-9905. Epub 2016 Oct 26.

PMID:
27748596
49.

Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.

Kumar M, Singh K, Naran K, Hamzabegovic F, Hoft DF, Warner DF, Ruminski P, Abate G, Chibale K.

ACS Infect Dis. 2016 Oct 14;2(10):714-725. Epub 2016 Sep 6.

PMID:
27737555
50.

Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction.

Njuguna NM, Umehara KI, Huth F, Schiller H, Chibale K, Camenisch G.

Drug Metab Pers Ther. 2016 Dec 1;31(4):221-228. doi: 10.1515/dmpt-2016-0028.

PMID:
27718490

Supplemental Content

Loading ...
Support Center